• Visara, a majority-owned ophthalmology subsidiary of NovaBridge Biosciences, secured an exclusive license to develop VIS-102 for neurotrophic keratitis.
• Rights cover worldwide markets excluding Greater China; VIS-102 is a modified recombinant human nerve growth factor designed for refrigerated, ready-to-use single doses.
• Deal expands Visara beyond VIS-101 in retinal vascular disease into ocular surface disease, broadening its ophthalmology pipeline.
• Hiteck receives an up-front payment, potential development and commercial milestones, and tiered royalties on net sales.
• Phase 1b data in severe neurotrophic keratitis showed 50% complete corneal healing at the highest dose after 8 weeks; vehicle control showed 14% at Week 4.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-419669), on October 13, 2026, and is solely responsible for the information contained therein.